Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MBX Biosciences, Inc. - Common Stock (NQ:MBX)

35.09 -2.59 (-6.87%)
Streaming Delayed Price Updated: 10:19 AM EST, Feb 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MBX Biosciences, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Amylyx Eyes $2B Opportunity In Post-Surgery Sugar Crash Market ↗
Guggenheim initiates Amylyx at Buy with $17 price forecast, citing PBH drug avexitide's Phase 3 potential and $2 billion+ market opportunity. 
Via Benzinga
News headline image
Earnings Scheduled For February 13, 2025 ↗
 
Via Benzinga
News headline image
These 5 Health Care Stocks Saw The Sharpest Retail Interest Jump Last Week ↗
These five small-cap pharma and biotech stocks drew heavy attention on Stocktwits last week, driven by key trial results, FDA updates, and promising drug developments. 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
Topics Economy
News headline image
Applied Digital, Vericel, Calavo Growers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Vision Marine Technologies Shares Are Trading Higher By 68%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
How Richard DiMarchi Revolutionized Diabetes Treatment ↗
Antiobesity drugs are amazing people by how fast they melt off pounds. But it's no surprise to Richard DiMarchi. 
Via Investor's Business Daily
News headline image
MBX Biosciences' Investigational Drug For Weight Loss Surgery-Related Low Blood Sugar Shows Encouraging Action ↗
MBX Biosciences reports Phase 1 trial results for MBX 1416, a GLP-1 receptor antagonist for post-bariatric hypoglycemia. Phase 2 starts in 2025. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For December 19, 2024 ↗
 
Via Benzinga
News headline image
StandardAero Surges In Market Debut ↗
Shares of StandardAero jumped 36% in the company's trading debut as the aircraft maintenance services provider raised $1.44 billion in its IPO. Additionally, Chain Bridge Bancorp opened on Oct. 5 at... 
Via Talk Markets
Topics Initial Public Offering
News headline image
Trio Of Biotech IPOs Climb In Debut ↗
A trio of biotech companies' shares rose on Friday in their first trading sessions. Bicara Therapeutics, MBX Biosciences, and Zenas BioPharma each sold more shares in their respective initial public... 
Via Talk Markets
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.